Skip to content

ESBE - PHARMA: what changed

Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.

What changed

ESBE - PHARMA

BE 0430.045.342
NACE 47.730, Retail sale of pharmaceutical products
fiscal year 2024 against 2025filed annual accounts (NBB)
Net result for the year
€113,949
2024 · €101,464+€12,485
Equity
€739,799
2024 · €625,734+€114,065
Cash
€601,816
2024 · €489,103+€112,713
Balance sheet total
€808,162
2024 · €698,204+€109,958

Largest movements

2024 to 2025
Assets
  • Cash +€112,713

    up €112,713 (+23.0%), from €489,103 to €601,816

    mainly Net result for the year (+€113,949) and Tax, wage and social debts (+€12,212)

  • Stocks and contracts +€12,968

    up €12,968 (+14.5%), from €89,516 to €102,484

Equity and liabilities
  • Reserves +€114,065

    up €114,065 (+19.7%), from €578,694 to €692,759

  • Tax, wage and social debts +€12,212

    up €12,212 (+49.0%), from €24,922 to €37,135

  • Other debts -€11,130

    down €11,130 (-83.4%), from €13,350 to €2,220

Income statement
  • Gross operating margin +€17,708

    up €17,708 (+10.4%), from €169,926 to €187,634

  • Taxes +€5,358

    up €5,358 (+10.8%), from €49,664 to €55,023

From the 2024 result to the 2025 result

effect on the result

Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.

Result 2024 €101,464
Gross operating margin +€17,708
Depreciation -€570
Other operating charges +€555
Financial income -€235
Financial charges +€385
Taxes -€5,358
Result 2025 €113,949

Cash bridge derived

cash 2024 to 2025

Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.

From operations +€110,670
Investment +€1,928
Financing +€116
Cash 2024 €489,103
Net result for the year +€113,949
Depreciation +€9,774
Stocks and contracts -€12,968
Receivables within one year -€1,306
Deferred charges and accrued income +€5,326
Trade debts -€5,187
Tax, wage and social debts +€12,212
Other debts -€11,130
Accrued charges and deferred income -€1
Investment in fixed assets (net) -€4,072
Current investments +€6,000
Contributions, distributions and other +€116
Cash 2025 €601,816
Every line side by side 43 lines
Line Code 2024 2025 Change %
Total assets 20/58 €698,204 €808,162 +€109,958 +15.7%
Fixed assets 21/28 €18,595 €12,893 -€5,702 -30.7%
Intangible fixed assets 21 €0 €0 =
Tangible fixed assets 22/27 €18,595 €12,893 -€5,702 -30.7%
Land and buildings 22 €0 €0 =
Plant, machinery and equipment 23 €10,265 €7,067 -€3,198 -31.2%
Furniture and vehicles 24 €8,330 €5,826 -€2,503 -30.1%
Other tangible fixed assets 26 €0 €0 =
Current assets 29/58 €679,609 €795,269 +€115,660 +17.0%
Stocks and contracts in progress 3 €89,516 €102,484 +€12,968 +14.5%
Stocks 30/36 €89,516 €102,484 +€12,968 +14.5%
Amounts receivable within one year 40/41 €827 €2,133 +€1,306 +157.9%
Trade receivables 40 €190 €1,243 +€1,053 +553.0%
Other amounts receivable 41 €637 €890 +€253 +39.7%
Current investments 50/53 €55,500 €49,500 -€6,000 -10.8%
Cash at bank and in hand 54/58 €489,103 €601,816 +€112,713 +23.0%
Deferred charges and accrued income 490/1 €44,662 €39,336 -€5,326 -11.9%
Total equity and liabilities 10/49 €698,204 €808,162 +€109,958 +15.7%
Equity 10/15 €625,734 €739,799 +€114,065 +18.2%
Contributions 10/11 €18,600 €18,600 = 0.0%
Reserves 13 €578,694 €692,759 +€114,065 +19.7%
Distributable reserves 133 €578,694 €692,759 +€114,065 +19.7%
Profit (loss) carried forward 14 €28,440 €28,440 = 0.0%
Amounts payable 17/49 €72,470 €68,363 -€4,106 -5.7%
Amounts payable within one year 42/48 €72,460 €68,355 -€4,105 -5.7%
Trade debts 44 €34,188 €29,001 -€5,187 -15.2%
Suppliers 440/4 €34,188 €29,001 -€5,187 -15.2%
Taxes, remuneration and social security 45 €24,922 €37,135 +€12,212 +49.0%
Taxes 450/3 €24,922 €37,135 +€12,212 +49.0%
Other amounts payable 47/48 €13,350 €2,220 -€11,130 -83.4%
Accrued charges and deferred income 492/3 €9 €8 -€1 -10.6%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €9,204 €9,774 +€570 +6.2%
Other operating charges 640/8 €3,301 €2,746 -€555 -16.8%
Gross operating margin 9900 €169,926 €187,634 +€17,708 +10.4%
Operating profit (loss) 9901 €157,421 €175,114 +€17,693 +11.2%
Financial income 75/76B €1,765 €1,530 -€235 -13.3%
Recurring financial income 75 €1,765 €1,530 -€235 -13.3%
Financial charges 65/66B €8,058 €7,673 -€385 -4.8%
Recurring financial charges 65 €8,058 €7,673 -€385 -4.8%
Profit (loss) for the period before taxes 9903 €151,128 €168,972 +€17,843 +11.8%
Income taxes 67/77 €49,664 €55,023 +€5,358 +10.8%
Profit (loss) for the period 9904 €101,464 €113,949 +€12,485 +12.3%
Profit (loss) for the period to be appropriated 9905 €101,464 €113,949 +€12,485 +12.3%

Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 September 2026 via checked.be.